RecruitingPhase 2NCT07219407

A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures

An Open-label, Long-term Study Evaluating RAP-219 in Adult Participants With Refractory Onset Seizures

Sponsor

Rapport Therapeutics Inc.

Enrollment

30 participants

Start Date

Dec 15, 2025

Study Type

INTERVENTIONAL

Conditions

seizure Epilepsy Refractory Focal Epilepsy Focal Epilepsy Focal Onset Seizure Focal Seizure

Summary

This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine RAP-219 Long- term safety and open-label antiseizure activity in patients with Refractory Focal Epilepsy.

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called RAP-219 for people with epilepsy, focal epilepsy, and other related conditions. The study is currently recruiting participants at 7 locations. People eligible for this study include aged 18 Years to 70 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRAP-219

Participants will receive one RAP-219 0.125 mg capsule daily for 3 days followed by one 0.25mg tablet RAP-219 daily for 28 days, then one 0.75mg tablet daily for the remainder of the treatment period.